David A. Santos - Jan 24, 2022 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role: EVP, Chief Commercial Officer
Signature: /s/ Dolly Vance (Attorney-in-Fact)
Stock symbol: RIGL
Transactions as of: Jan 24, 2022
Transactions value $: $0
Form type: 4
Date filed: 1/26/2022, 07:45 PM
Next filing: Dec 30, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RIGL	Common Stock	Award	$0	+50K	+500%	$0.00	60K	Jan 24, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RIGL	Stock Option (Right to Buy)	Award	$0	+100K		$0.00	100K	Jan 24, 2022	Common Stock	100K	$2.42	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from February 1, 2022, with the first annual vest occurring on February 1, 2023.
F2	Includes 10,000 shares acquired under the Issuer's stock purchase plan.
F3	The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2022, subject to the reporting person's continuous service to the issuer through each such period.